|
New IPO, ZymeTx, Inc. develops, manufactures and markets proprietary biotechnology products that specifically target enzyme active sites on viruses. Their first procduct, ZStatFlu diagnostic test, will be the first useful test for influenza that can be used in a doctor's office. This flu diagnosticw ill be a cost-effective tool to manage the 200 million cases of upper respiratory infections presented to doctors each year. Currently, many cases of influenza are treated with antibiotics, even though antibiotics are completely ineffective for viral infections. Managed care organizations are the first target market for ZStatFlu because of the dramatic cost savings. Float is 2.3 million shares, outstanding 7.69 million. In September the comapny received clearance from the FDA to market ZStatFlu. The product is being manufactured and will be sold to managed care organizations in the U.S. and Europe during the flu season this winter. There are 200 million upper respiratory infections presented in the U.S. each year and this is the first tool to effectively manage them. The incidence of antibiotic resistance is growing at an alarming rate. ZStatFlu can slow this process by limiteg the unnecessary prescribing of antibiotics when viral disease is present. |
